Clinical Trials Browser

Phase 2/3 × Completed × Fulvestrant × Clear all

NCT02692755 2021-09-28

PALINA

Phase 2/3 Completed

35 enrolled 12 charts

Hormone Receptor Positive HER-2 Negative Breast Cancer

NCT02116803 2018-03-01

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

Phase 2/3 Completed

12 enrolled 6 charts

Neoplasms